Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more
Genmab A/S (GNMSF) - Total Liabilities
Latest total liabilities as of September 2025: $1.27 Billion USD
Based on the latest financial reports, Genmab A/S (GNMSF) has total liabilities worth $1.27 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genmab A/S - Total Liabilities Trend (2002–2024)
This chart illustrates how Genmab A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genmab A/S Competitors by Total Liabilities
The table below lists competitors of Genmab A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Straumann Holding AG
PINK:SAUHF
|
USA | $1.45 Billion |
|
Five Below Inc
NASDAQ:FIVE
|
USA | $2.84 Billion |
|
UltraTech Cement Limited
PINK:UCLQF
|
USA | $598.04 Billion |
|
Jack Henry & Associates Inc
NASDAQ:JKHY
|
USA | $856.99 Million |
|
AP Moeller - Maersk A/S A
PINK:AMKAF
|
USA | $31.66 Billion |
|
XCMG Construction Machinery Co Ltd
SHE:000425
|
China | CN¥118.31 Billion |
|
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
F:SAJA
|
Germany | €53.28 Billion |
|
WEG S.A
SA:WEGE3
|
Brazil | R$18.08 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Genmab A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genmab A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genmab A/S (2002–2024)
The table below shows the annual total liabilities of Genmab A/S from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.11 Billion | +147.73% |
| 2023-12-31 | $3.68 Billion | +29.68% |
| 2022-12-31 | $2.84 Billion | +16.70% |
| 2021-12-31 | $2.43 Billion | +20.23% |
| 2020-12-31 | $2.02 Billion | +84.49% |
| 2019-12-31 | $1.10 Billion | +145.39% |
| 2018-12-31 | $446.64 Million | +35.04% |
| 2017-12-31 | $330.75 Million | -19.63% |
| 2016-12-31 | $411.54 Million | -1.03% |
| 2015-12-31 | $415.83 Million | -50.13% |
| 2014-12-31 | $833.74 Million | -22.23% |
| 2013-12-31 | $1.07 Billion | -18.15% |
| 2012-12-31 | $1.31 Billion | +21.49% |
| 2011-12-31 | $1.08 Billion | -23.08% |
| 2010-12-31 | $1.40 Billion | +51.63% |
| 2009-12-31 | $924.34 Million | -13.64% |
| 2008-12-31 | $1.07 Billion | -0.48% |
| 2007-12-31 | $1.08 Billion | +445.81% |
| 2006-12-31 | $197.05 Million | -21.70% |
| 2005-12-31 | $251.66 Million | +176.79% |
| 2004-12-31 | $90.92 Million | -2.94% |
| 2003-12-31 | $93.67 Million | -49.08% |
| 2002-12-31 | $183.97 Million | -- |